Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Save your unit preferences in settings!

    Eastern Cooperative Oncology Group (ECOG) Performance Status

    Determines ability of patient to tolerate therapies in serious illness, specifically for chemotherapy, simpler than the Karnofsky Scale.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with active cancer under treatment.

    • The ECOG Performance Status is a simple measure of functional status.
    • It has scores ranging from 0 to 5, and these correlate with scores from the Karnofsky Scale’s 0-100 scores.
    • It is commonly used as a prognostic tool, as a selection criterion for cancer research, and to help determine treatment.

    Performance status is highly correlated with survival, need for services, and may help predict ability to tolerate therapies.

    Asymptomatic
    Symptomatic but completely ambulatory
    Symptomatic, <50% in bed during the day
    Symptomatic, >50% in bed, but not bedbound
    Bedbound
    Death

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The ECOG Performance Status may be slightly better than Karnofsky for discriminating prognostically and, as an adaptation of Karnofsky, is likely to be at least similar in other domains. It is also simpler to use, and therefore may be preferred.

    Management

    We are unaware of validated management algorithms using the ECOG Performance Status.

    Critical Actions

    The ECOG Performance Status and other performance scales should be used in the holistic assessment of cancer patients, though their accuracy as prognostic tools in individual cases is not yet proved.

    About the Creator
    Dr. Martin Oken
    Are you Dr. Martin Oken?